Heidelberg Pharma AG

LSE:0QW5 Stock Report

Market Cap: €114.6m

Heidelberg Pharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Andreas Pahl

Chief executive officer

€450.7k

Total compensation

CEO salary percentage53.3%
CEO tenureless than a year
CEO ownershipn/a
Management average tenure1.8yrs
Board average tenure12.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Andreas Pahl's remuneration changed compared to Heidelberg Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Aug 31 2024n/an/a

-€19m

May 31 2024n/an/a

-€13m

Feb 29 2024n/an/a

-€18m

Nov 30 2023€451k€240k

-€20m

Aug 31 2023n/an/a

-€22m

May 31 2023n/an/a

-€27m

Feb 28 2023n/an/a

-€19m

Nov 30 2022€328k€240k

-€20m

Aug 31 2022n/an/a

-€21m

May 31 2022n/an/a

-€22m

Feb 28 2022n/an/a

-€27m

Nov 30 2021€442k€240k

-€26m

Aug 31 2021n/an/a

-€25m

May 31 2021n/an/a

-€22m

Feb 28 2021n/an/a

-€20m

Nov 30 2020€295k€207k

-€18m

Aug 31 2020n/an/a

-€17m

May 31 2020n/an/a

-€15m

Feb 29 2020n/an/a

-€12m

Nov 30 2019€288k€200k

-€10m

Aug 31 2019n/an/a

-€10m

May 31 2019n/an/a

-€11m

Feb 28 2019n/an/a

-€12m

Nov 30 2018€286k€200k

-€12m

Compensation vs Market: Andreas's total compensation ($USD464.41K) is above average for companies of similar size in the UK market ($USD346.45K).

Compensation vs Earnings: Andreas's compensation has increased whilst the company is unprofitable.

CEO

Andreas Pahl

less than a year

Tenure

€450,663

Compensation

Prof. Dr. Andreas Pahl is Chief Executive Officer & Spokesman of the Executive Board at Heidelberg Pharma AG since February 1, 2024 and had been its Chief Scientific Officer and Member of the Executive Man...

Leadership Team

NamePositionTenureCompensationOwnership
Andreas Pahl
CEO & Spokesman of the Executive Boardless than a year€450.66kno data
Walter Miller
Chief Financial Officer1.7yrs€398.63kno data
Jorg Kemkowski
Chief Operating Officer2yrsno datano data
Sylvia Wimmer
Director Corporate Communicationno datano datano data
Andras Strassz
Chief Medical Officer3.8yrsno datano data
George Badescu
Chief Business Officerno datano datano data

1.8yrs

Average Tenure

Experienced Management: 0QW5's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Friedrich von Bohlen und Halbach
Member of the Supervisory Board19.8yrs€18.00kno data
Georg Baur
Deputy Chairman of the Supervisory Board25yrs€38.00kno data
Christof Hettich
Chairman of Supervisory Board14.7yrs€49.50kno data
Birgit Kudlek
Member of the Supervisory Board12.7yrs€21.75kno data
Mathias Hothum
Deputy Chairman of Supervisory Board9.5yrs€39.00kno data
Dongzhou Liu
Member of Supervisory Board2.6yrs€21.00kno data
Yan Xia
Member of Supervisory Board1.7yrs€9.96kno data

12.7yrs

Average Tenure

59.5yo

Average Age

Experienced Board: 0QW5's board of directors are seasoned and experienced ( 12.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 10:07
End of Day Share Price 2025/01/03 00:00
Earnings2024/08/31
Annual Earnings2023/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Heidelberg Pharma AG is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruno BulicBaader Helvea Equity Research
Christian WeizBaader Helvea Equity Research
Gregory RamirezBryan Garnier & Co